title: Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection.
abstract: The goal of this study was to evaluate the protective efficacy of a cationic nanoparticle-based DNA vaccine expressing antigen 85A (Ag85A) and 6-kDa early secretory antigen target (ESAT-6) of Mycobacterium tuberculosis as well as cytokine interleukin-21 (IL-21) against M. tuberculosis infection. The results of this indicated that the anti-M. tuberculosis immune responses were induced in mice that had received the different DNA vaccines. More importantly, compared with using DNA vaccine Ag85A-ESAT-6-IL-21 alone, the nanoparticle-based DNA vaccine Ag85A-ESAT-6-IL-21 showed a statistically significant increase in the protective efficacy against M. tuberculosis infection in the immunized mice. We concluded that the nanoparticle-based DNA vaccine induced a strong immune response and markedly inhibited the growth of the M. tuberculosis in the mice. These findings highlighted the potential utility of Fe3O4-Glu-polyethyleneimine nanoparticles encapsulated with the DNA vaccine as a prophylactic vaccine in the M. tuberculosis-infected mouse model.
  
  
  BACKGROUND
  This study emphasizes the potential utility of Fe3O4-Glu-polyethyleneimine nanoparticles encapsulated with DNA vaccine against TB as a prophylactic vaccine. The authors demonstrated a strong immune response and marked growth inhibition of mycobacterium tuberculosis in the mice.
authors.affiliation: Department of Pathogenic Biology and Immunology, Medical School, Southeast University, Nanjing, China.
authors.forename: Fangliu
authors.initials: F
authors.lastname: Yu
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Dou
authors.forename: Haitao
authors.initials: H
authors.lastname: Yang
authors.forename: Xingfeng
authors.initials: X
authors.lastname: He
authors.forename: Weiguo
authors.initials: W
authors.lastname: Xu
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.forename: Kai
authors.initials: K
authors.lastname: Hu
authors.forename: Ning
authors.initials: N
authors.lastname: Gu
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D006801:Humans; D007378:Interleukins / Q000737:chemistry / Q000276:immunology; D008297:Male; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000276:immunology / Q000472:pathogenicity; D053758:Nanoparticles / Q000737:chemistry*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000276:immunology; D014376:Tuberculosis / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D032581:Tuberculosis Vaccines / Q000008:administration & dosage / Q000276:immunology; D019444:Vaccines, DNA / Q000737:chemistry / Q000276:immunology; D000098546:Interleukin-21
chemical_list: D000276:Adjuvants, Immunologic; C557979:Ag85B-ESAT-6 fusion antigen; D007378:Interleukins; D011993:Recombinant Fusion Proteins; D032581:Tuberculosis Vaccines; D019444:Vaccines, DNA; D000098546:Interleukin-21